Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of targeted therapies as a preferred treatment approach for newly diagnosed chronic lymphocytic leukemia (CLL) has significantly transformed the treatment landscape of relapsed/refractory disease. The selection of treatment for patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) should be based on the type of first-line therapy and the duration of remission to first-line therapy, in addition to the patient (age and functional status) and disease (clinical stage, cytogenetic, or molecular features) characteristics. The benefit/risk of continuous vs fixed-treatment approach should be carefully evaluated, and sequencing of therapy, when done appropriately, can improve response rates and treatment tolerance in patients with previously treated CLL/SLL. Clinicians are challenged to remain up-to-date about the recent clinical advances that can help them make informed clinical decisions for individual patients to optimize clinical outcomes.
Target Audience
This activity is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
Following this program, participants should be able to:
- Review the current treatment options for patients with newly-diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Discuss the available evidence on sequencing therapy for patients with previously treated CLL/SLL and develop an individualized treatment plan for patients with relapsed/refractory disease.
- Identify the rationale for the use of chemotherapy-free combination regimens and summarize the evidence from recent clinical trials evaluating combination regimens.
Jennifer R. Brown, MD, PhD
Dana-Farber Cancer Institute
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
Presenting Faculty
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Jennifer R. Brown, MD, PhD
AbbVie, Inc.: Consulting Fee
Acerta/AstraZeneca: Consulting Fee
BeiGene: Consulting Fee
Bristol-Myers Squibb/Juno/Celgene: Consulting Fee
Catapult Therapeutics: Consulting Fee
Eli Lilly and Company: Consulting Fee
Genentech/Roche: Consulting Fee
Gilead Sciences, Inc.: Grant/Research Support
Invectys Inc.: Scientific Advisor
Janssen Pharmaceutica Products, LP: Consulting Fee
Loxo/Lilly: Grant/Research Support
MEI Pharma Inc.: Consulting Fee
MorphoSys AG: Consulting Fee
Nextcea, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee
Rigel Pharmaceuticals, Inc.: Consulting Fee
Secura Bio: Grant/Research Support
Sun Pharma: Grant/Research Support
TG Therapeutics, Inc.: Grant/Research Support
Moderator
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Jeremy S. Abramson, MD, MMSc
Allogene Therapeutics: Consulting Fee
AstraZeneca Pharmaceuticals LP: Honoraria
BeiGene: Consulting Fee; Honoraria
bluebird bio, Inc.: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support; Honoraria
Celgene Corporation: Consulting Fee; Grant/Research Support; Honoraria
C4 Therapeutics, Inc.: Consulting Fee
Epizyme, Inc.: Consulting Fee
Genentech, Inc.: Consulting Fee
Genmab A/S: Honoraria
Incyte Corporation: Honoraria
Karyopharm Therapeutics: Consulting Fee
Kite Pharma: Consulting Fee
Kymera Therapeutics: Consulting Fee
MorphoSys AG: Consulting Fee
Mustang Bio: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Ono Pharmaceutical Co., Ltd.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Honoraria
Seattle Genetics, Inc.: Grant/Research Support
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-122-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until December 15, 2022. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing